证券代码：300204 证券简称：舒泰神 公告编号：2025-075 舒泰神（北京）生物制药股份有限公司 关于股东部分股份解除质押及再质押的公告 公司持股 5%以上股东香塘集团有限公司保证信息披露内容的真实、准确和 完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 舒泰神（北京）生物制药股份有限公司（以下简称"本公司"或"舒泰神"） 近日接到持股 5%以上股东香塘集团有限公司（以下简称"香塘集团"）函告，获 悉香塘集团将其所持有本公司的部分股份解除质押及再质押，具体事项如下： 五、备查文件 1、中国证券登记结算有限责任公司股份冻结明细； 2、深交所要求的其他文件。 二、股东股份质押的基本情况 | 股东 | 是否为控 股股东或 第一大股 | 本次质 押数量 | 占其所 持股份 | 占公司 总股本 | 是否为 | 质押起 | 质押到 | 质权人 | 用途 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | | （万 | | | 限售股 | 始日期 | 期日期 | ...

Core Insights - A total of 490 stocks in the Shanghai and Shenzhen markets have experienced net outflows of main funds for five consecutive days or more as of October 29 [1] - The stock with the longest continuous net outflow is Zhongju Gaoxin, with 31 days of outflows, followed by Hengshen New Materials with 21 days [1] - The largest total net outflow amount is from China Merchants Bank, with a cumulative outflow of 3.093 billion yuan over 12 days [1] Group 1: Stocks with Longest Net Outflows - Zhongju Gaoxin has seen net outflows for 31 days, with a total outflow of 559 million yuan and a cumulative decline of 6.91% [1] - Hengshen New Materials has recorded net outflows for 21 days, totaling 197 million yuan, with a decline of 9.80% [3] - China Merchants Bank has the highest net outflow amount of 3.093 billion yuan over 12 days, with a net outflow ratio of 6.98% and a cumulative increase of 1.65% [1] Group 2: Other Notable Stocks - Guotai Junan has experienced net outflows for 10 days, amounting to 1.877 billion yuan, with a net outflow ratio of 7.89% and a cumulative increase of 2.70% [1] - Shengbang Co. has seen net outflows for 12 days, totaling 1.826 billion yuan, with a net outflow ratio of 9.52% and a cumulative decline of 10.65% [1] - Huajian Group has recorded net outflows for 6 days, with a total outflow of 1.713 billion yuan and a significant decline of 40.29% [1] Group 3: Stocks with Significant Outflow Ratios - Jianan Intelligent has the highest net outflow ratio at 14.74%, with a decline of 2.98% over the past 5 days [1] - Other notable stocks with high outflow ratios include Huayi Development at 11.91% and Pianzaihuang at 11.84% [1] - The overall trend indicates a significant outflow of funds from various sectors, reflecting investor sentiment and market conditions [1]

舒泰神表示，营收下降主要由于本期产品销售减少所致。 北京商报讯（记者 丁宁）10月28日晚间，舒泰神（300204）发布2025年三季报显示，公司前三季度实 现营业收入1.81亿元，同比下降30.82%；归属净利润-3068.95万元，同比下降227.71%。 ...

Core Viewpoint - The company reported a significant decline in revenue and incurred net losses in the first three quarters of 2025 compared to the previous year [1] Financial Performance - The company's operating revenue for the first three quarters was 181 million yuan, representing a year-on-year decrease of 30.82% [1] - The net loss attributable to shareholders of the listed company was 30.6895 million yuan [1] - The net loss attributable to shareholders after deducting non-recurring gains and losses was 34.3569 million yuan [1] - The basic loss per share was 0.06 yuan [1]

Company Overview - Shuyou Shen (SZ 300204) announced on October 28 that its sixth board meeting will be held in Beijing, where the third quarter report for 2025 will be reviewed [1] - As of the announcement, Shuyou Shen's market capitalization is 16.2 billion yuan [1] Financial Performance - For the year 2024, Shuyou Shen's revenue composition is entirely from product sales, accounting for 100.0% [1]

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 舒泰神（北京）生物制药股份有限公司 2025 年第三季度报告全文已于 2025 年 10 月 29 日在中国证监会指定的创业板信息披露网站上披露，请投资者注意查 阅。 特此公告 舒泰神（北京）生物制药股份有限公司 证券代码：300204 证券简称：舒泰神 公告编号：2025-073 舒泰神（北京）生物制药股份有限公司 关于 2025 年第三季度报告披露的提示性公告 董事会 2025 年 10 月 29 日 ...

证券代码：300204 证券简称：舒泰神 公告编号：2025-074 舒泰神（北京）生物制药股份有限公司 第六届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 舒泰神（北京）生物制药股份有限公司（以下简称"舒泰神"或"公司"） 第六届董事会第十次会议（以下简称"本次会议"）通知以电话、电子邮件等相结 合的方式于 2025 年 10 月 22 日发出，本次会议于 2025 年 10 月 28 日上午 09:00 在北京经济技术开发区经海二路 36 号公司会议室，以现场结合通讯方式召开。 本次会议应出席董事 9 名，实际出席董事 9 名，现场表决的董事 8 名，通讯表决 的董事 1 名。公司高级管理人员列席了会议。本次会议的召集与召开符合《中华 人民共和国公司法》（以下简称"《公司法》"）和《舒泰神（北京）生物制药股份 有限公司章程》（以下简称"《公司章程》"）的有关规定。 本次会议由董事长周志文先生召集和主持，与会董事经过充分讨论和认真审 议，一致同意并通过了如下决议： 一、审议通过《舒泰神（北京）生物制药股份有限公司 2025 年第三 ...

Financial Performance - Revenue for Q3 2025 was ¥54,941,098.61, a decrease of 30.10% compared to the same period last year[4] - Net profit attributable to shareholders was -¥6,053,967.38, a decline of 1.89% year-over-year[4] - The company reported a net cash flow from operating activities of -¥107,047,029.72, a decrease of 332.81% year-to-date[4] - Operating income decreased by ¥80,449,514.04, a decline of 30.82% attributed to reduced product sales[10] - Total operating revenue for the period was ¥180,538,395.51, a decrease of 30.8% compared to ¥260,987,909.55 in the previous period[34] - The net profit for the current period is -37,879,165.05, compared to -9,364,956.52 in the previous period, indicating a significant increase in losses[35] - Operating profit for the current period is -37,392,767.69, compared to -8,614,783.75 in the previous period, reflecting a worsening operational performance[35] - Total comprehensive income for the current period is -53,467,389.71, compared to 16,012,131.45 in the previous period, showing a substantial decline[36] - Cash flow from operating activities shows a net outflow of -107,047,029.72, compared to -24,733,298.84 in the previous period, indicating increased cash burn[38] Assets and Liabilities - Total assets increased to ¥1,263,925,202.35, reflecting a growth of 9.94% from the end of the previous year[5] - Total assets reached ¥1,263,925,202.35, up from ¥1,149,607,757.17, reflecting a growth of 9.9%[32] - Total liabilities increased to ¥404,224,404.94 from ¥232,846,415.32, a rise of 73.3%[32] - The company's total equity decreased to ¥859,700,797.41 from ¥916,761,341.85, a decline of 6.2%[32] Cash and Cash Equivalents - Cash and cash equivalents increased by ¥104,087,711.75, a rise of 193.07% due to new investments received[9] - Cash and cash equivalents increased to ¥157,998,891.79 from ¥53,911,180.04, representing a growth of 192.5%[30] - Cash and cash equivalents at the end of the period amount to 157,410,459.27, up from 42,731,525.34 in the previous period, reflecting improved liquidity[38] Accounts Receivable and Inventory - Accounts receivable increased by ¥11,722,383.16, up 8,071.18% primarily due to reduced bank acceptance bill payments[9] - Accounts receivable decreased to ¥33,804,624.73 from ¥38,928,239.79, a decline of 13.5%[30] - Inventory rose to ¥30,096,329.85 from ¥22,181,013.09, an increase of 35.9%[31] Expenses - Financial expenses surged by ¥4,721,576.68, an increase of 11,906.93% due to the recognition of financial liabilities related to share repurchase obligations[10] - Research and development expenses for the same period were 82.60 million yuan, down 24.99% from 110.13 million yuan in 2024[17] - Research and development expenses for the current period are 58,104,013.78, down from 77,690,259.04 in the previous period, suggesting a reduction in investment in innovation[35] - Sales expenses decreased to 89,004,469.80 from 114,566,444.96, indicating cost-cutting measures in sales operations[35] Tax and Other Income - Income tax expenses increased by CNY 79,212.36, a growth of 11,527.33% year-over-year, primarily due to accelerated depreciation of fixed assets leading to deferred income tax[11] - Other comprehensive income after tax changed from CNY 25,377,087.97 in the same period last year to CNY -15,588,224.66 this period, a change of CNY -40,965,312.63, representing a 161.43% change, mainly due to fair value changes of other equity instruments[11] - Cash received from sales of goods and services decreased by CNY 102,998,067.71, a decline of 38.75% year-over-year, primarily due to reduced product sales[11] - Cash received from tax refunds decreased by CNY 1,574,494.77, a decline of 89.44% year-over-year, mainly due to last year's receipt of tax refunds[11] - Cash received from other operating activities decreased by CNY 2,254,077.84, a decline of 42.93% year-over-year, primarily due to reduced cash flow from operating activities[11] - Cash received from investment income decreased by CNY 474,528.17, a decline of 93.42% year-over-year, mainly due to reduced income from other equity investments[11] - Cash received from the disposal of fixed assets increased by CNY 1,643,966.32, an increase of 1,007.76% year-over-year, primarily due to increased disposals of fixed assets[11] - Cash received from investments increased from CNY 0 to CNY 133,333,300.00, primarily due to investments received from Wuxi Jinyi Yuanli Equity Investment Partnership[11] - Cash received from borrowings increased from CNY 0 to CNY 41,644,342.43, primarily due to bank loans received this period[11] - Cash received from other financing activities increased by CNY 50,340,840.00, an increase of 308.35% year-over-year, mainly due to the disposal of partial subsidiary equity without losing control[11] Clinical Trials and Product Development - The STSA-1002 injection for acute respiratory distress syndrome showed preliminary efficacy with a 28-day all-cause mortality rate of 26.67% in the low-dose group, compared to 40.00% in the control group[22] - The BDB-001 injection for ANCA-associated vasculitis demonstrated a 12-week partial remission rate of 76.5% in the high-dose group, comparable to the standard treatment group[23] - The overall incidence of serious adverse events for BDB-001 was 24.7%, with the lowest rate in the low-dose group at 6.3%[23] - The company plans to advance the Phase III clinical trial for BDB-001 based on current data indicating significant clinical benefits[23] - The STSP-0902 eye drops showed good safety and tolerability in healthy subjects, supporting further clinical trials in patients with neurotrophic keratitis[24] Corporate Governance and Plans - The company announced a board meeting to elect a non-independent director, maintaining the number of independent directors at three[25] - The company approved a plan for a targeted stock issuance to specific investors during the board meeting held on September 8, 2025[25] - The company announced plans for a private placement of shares, pending approval from regulatory authorities[26] - The election of Mr. Zheng Hong as the employee representative director was confirmed, ensuring compliance with legal requirements[27] Audit and Reporting - The company has not undergone an audit for the third quarter financial report[39]

Core Viewpoint - Shuyou Shen (300204) plans to issue shares to specific investors to raise up to 1.253 billion yuan for innovative drug research and working capital, following approval from the board and shareholders [3][5]. Group 1: Financial Performance - As of December 31, 2024, the company's total consolidated assets amounted to 1,149.61 million yuan, with total liabilities of 232.85 million yuan and equity attributable to shareholders of 929.23 million yuan [2]. - For the fiscal year 2024, the company reported a consolidated revenue of 324.82 million yuan and a net loss of 147.73 million yuan, with a negative cash flow from operating activities of 63.68 million yuan [2]. - The company has experienced continuous net losses over the past three years, with a net loss of 24.64 million yuan in the first half of 2025 [4]. Group 2: Stock Issuance Details - The planned share issuance will not exceed 143,331,766 shares, representing 30% of the total share capital prior to the issuance, with a minimum issuance price set at 80% of the average trading price over the previous 20 trading days [3][5]. - The funds raised will be allocated as follows: 883 million yuan for clinical research and registration of innovative drugs (BDB-001, STSA-1002, STSP-0902) and 370 million yuan for working capital [5]. - The issuance is subject to approval from the Shenzhen Stock Exchange and registration with the China Securities Regulatory Commission [4][5]. Group 3: Market Activity - On October 27, 2025, Shuyou Shen's stock closed at 34.13 yuan, with a trading volume of 342,800 shares and a turnover of 1.189 billion yuan [1]. - The net outflow of funds from major investors on the same day was 57.71 million yuan, while retail investors saw a net inflow of 95.75 million yuan [2][4].

Core Points - Shuyou Shen (300204) reported a closing price of 34.13 yuan on October 27, 2025, with a market capitalization of 16.306 billion yuan, reflecting a 0.47% increase from the previous trading day [1] - The company announced a plan to issue shares to specific investors, aiming to raise no more than 1.253 billion yuan for innovative drug research and to supplement working capital [1] - The share issuance will not exceed 30% of the total share capital prior to issuance, amounting to 143,331,766 shares, and has been approved by the board and shareholders, pending review by the Shenzhen Stock Exchange and registration with the CSRC [1] Financial Details - The funds raised will allocate 883 million yuan for clinical research and registration of innovative drugs BDB-001, STSA-1002, and STSP-0902, while 370 million yuan will be used to supplement working capital [1] - The issuance will not result in a change of control for the company and does not constitute a major asset restructuring [1] Risk Factors - The company has indicated potential risks including performance losses and the possibility that fundraising projects may not meet expectations [1]